MDSpire - Summary
Feature

The Past, Present and Future of Non-Target Screening

Thomas Letzel reflects on the evolution of non-target screening and why interdisciplinary insights are key to its future

  • March 23, 2026

  • 9 min

Share

Non-target screening (NTS) has emerged as a significant analytical approach across diverse fields, including metabolomics and environmental science. Thomas Letzel, the founder of AFIN-TS and associate professor at the Technical University of Munich, emphasizes NTS's evolving importance, addressing complex data challenges and interdisciplinary collaboration. He highlights NTS's role in identifying unknown substances and notes ongoing training initiatives to enhance its implementation. The upcoming roundtable symposium aims to foster understanding of NTS advancements and applications across sectors.

Original Source(s)

The Past, Present and Future of Non-Target Screening

  • March 23, 2026

Related Content

Metabolic Acidosis Care Limited in Chronic Kidney Disease

Low testing rates may contribute to underdiagnosis and undertreatment in Japan

Influencer Drug Promotion Raises Concerns

Study highlights regulatory gaps and persuasive risks in social media marketing

From Crisis to Compliance: Navigating Europe’s Toughest Medical Device Rules

Compliance is no longer a background function — it is central to maintaining access